Fig. 8.
Effect of combination therapies with multi-kinase inhibitor and/or checkpoint inhibitors (anti-PD1 and anti-CTLA4) on PCTS from patient 141: tumour slices had reduced cell proliferation in response to immunotherapy within 8 days of culture. Tissue slices from pt 141 were treated with doxorubicin (positive control, red), nivolumab + regorafenib (pink), nivolumab + ipilimumab (blue) and atezolizumab + bevacizumab (purple) for the indicated time and compared to untreated PCTS (black). The following parameters were assessed in nPCTS = 3 per timepoint. a | Cell proliferation: percentage of Ki67 positive cells in tissue slices treated with indicated drug combinations; mean ± SD. b | Apoptosis: percentage of TUNEL positive cells in tissue slices treated with indicated drug combinations; mean ± SD. c | Representative images of H&E, Ki67 and TUNEL staining. Statistical test: 2-way ANOVA. Scale bars: 100 μm.